Clinical pharmacology of etoposide in children undergoing autologous stem cell transplantation for various solid tumours

1. The population pharmacokinetics of high-dose etoposide was studied in a group of young children and adolescents. 2. Twenty-six children and adolescent were administered high-dose etoposide as a continuous infusion over 24 h. Etoposide plasma concentration-time data was modelled using NONMEM® 7. The effect of age, weight, serum creatinine (SCr), and gender on pharmacokinetic parameters (CL and Vd) were determined by a nonlinear mixed effect model. 3. The pharmacokinetics of etoposide based on BSA dosing was best described with a 1-compartment structural model which was parameterised in terms of clearance (CL) and volume of distribution (Vd). An exponential error model was used to explain intersubject variability and a proportional error model was used to describe residual or intrapatient variability. The final model parameter estimates for the typical (normalised to 70 kg) values of CL and Vd were 2.31 L/hr and 17.5 L, respectively. The CL and Vd allometrically increased with weight with the power of 3/4 and 1, respectively. After accounting for weight dependence using the allometric scaling, age, serum creatinine, and gender did not have any influence on model parameters. 4. The results of this children and adolescent population pharmacokinetic study indicates that etoposide pharmacokinetics were influenced by body weight on an allometric basis. The pharmacokinetic parameters CL and Vd increased with increasing weight similar to BSA.

[1]  M. Heyman,et al.  Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia – a multicentre study from the Nordic Society of Paediatric Haematology and Oncology , 2015, British journal of haematology.

[2]  J. Hainsworth,et al.  High-dose etoposide: from phase I to a component of curative therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Palle,et al.  Etoposide pharmacokinetics in children treated for acute myeloid leukemia , 2006, Anti-cancer drugs.

[4]  Iftekhar Mahmood,et al.  Prediction of drug clearance in children from adults: a comparison of several allometric methods. , 2006, British journal of clinical pharmacology.

[5]  G. Hale Autologous hematopoietic stem cell transplantation for pediatric solid tumors , 2005, Expert review of anticancer therapy.

[6]  Y. Nieto,et al.  Pharmacokinetics of high-dose chemotherapy , 2004, Bone Marrow Transplantation.

[7]  N. Sakura,et al.  Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents , 2003, Pediatrics international : official journal of the Japan Pediatric Society.

[8]  B. Hero,et al.  High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma , 2002, Bone Marrow Transplantation.

[9]  T. Klingebiel,et al.  Population pharmacokinetics of high-dose etoposide in children receiving different conditioning regimens , 2002, Anti-cancer drugs.

[10]  A. Adjei,et al.  The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours , 2001, British Journal of Cancer.

[11]  L. Madero,et al.  High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors , 1999, Bone Marrow Transplantation.

[12]  P. Gwilt,et al.  Assay for etoposide in human serum using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[13]  S. Feig,et al.  Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  F. Berthold,et al.  Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Madden,et al.  Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Cole,et al.  Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation. , 1993, Cancer research.

[17]  W. Evans,et al.  Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. , 1984, Cancer research.

[18]  M. Kletzel,et al.  Pediatric transplantation: results in solid tumors. , 2005, Current hematology reports.

[19]  F. Cavalli,et al.  Pharmacokinetics of VP16-213 given by different administration methods , 2004, Cancer Chemotherapy and Pharmacology.

[20]  A. Look,et al.  Pharmacokinetics of teniposide (VM26) and etoposide (VP16-213) in children with cancer , 2004, Cancer Chemotherapy and Pharmacology.

[21]  H. McLeod,et al.  Handbook of Anticancer Pharmacokinetics and Pharmacodynamics , 2004, Cancer Drug Discovery and Development.

[22]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.

[23]  W. Evans,et al.  Pharmacokinetics of anticancer drugs in children. , 1983, Drug metabolism reviews.